Skip to content

Managing Toxicities in Novel Anticancer Therapies: A Health care Professional Survey

Thank you for participating in this survey hosted by CancerNetwork and Oncology Nursing News. As oncology treatments evolve, managing toxicities from novel therapies like monoclonal antibodies, bispecific antibodies, CAR T-cell therapies, and immunotherapies presents unique challenges.
Your insights will help us better understand common toxicities and current management strategies, guiding improvements in resources and care.

We appreciate your time and expertise. Let’s begin!
1.As someone who is helping to manage patients’ toxicities related to their cancer treatment, what type of health care professional category do you fall under?(Required.)
2.What are the most common adverse effects that you have observed in patients treated with monoclonal antibodies? Please specify the drug and the adverse effect.(Required.)
3.What are the most common adverse effects that you have observed in patients treated with bispecific antibodies? Please specify the drug and the adverse effect.(Required.)
4.Based on the previously question, are there any other adverse effects that you have observed in patients treated with bispecific antibodies? Please specify the drug and the adverse effect.(Required.)
5.What are the most common adverse effects that you have observed in patients treated with CAR T-cell therapies? Select all that apply.(Required.)
6.What are the most common adverse effects you have observed in patients treated with immunotherapies? Select all that apply.(Required.)
7.How do you typically manage cytokine release syndrome (CRS) and neurotoxicity in patients receiving CAR T-cell therapy? Please describe your management protocols.(Required.)
8.What strategies do you employ to manage immune-related adverse effects associated with immunotherapies, such as pneumonitis, colitis, or endocrinopathies?(Required.)
9.How do you approach the management of hematological toxicities, particularly cytopenias, in patients treated with bispecific antibodies?(Required.)
10.What are the most challenging or unique adverse effects you have encountered with these newer agents, and what are the current limitations in management?(Required.)
11.What are your primary sources of information for managing toxicities associated with these newer oncology agents? Select all that apply.(Required.)
12.Do you feel that you have adequate access to resources and information to effectively manage these toxicities? Please explain your answer.
Privacy & Cookie Notice